A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Science Translational Medicine

• Publication date

  2017-11-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/scitranslmed.aan6566PMID 29141884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• EGFR Exon 18 Mutations in Lung Cancer：Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

  2017cited by this paper
• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

  2016cited by this paper
• Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.

  2016cited by this paper
• High-throughput Phenotyping of Lung Cancer Somatic Mutations.

  2016cited by this paper
• EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

  2016cited by this paper
• EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

  2016cited by this paper
• Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

  2015cited by this paper
• EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

  2015cited by this paper
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

  2015cited by this paper
• Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M

  2015cited by this paper
• EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• The future of cancer genomics

  2015cited by this paper
• Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

  2015cited by this paper
• Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

  2014influential reference
• Alectinib Shows Potent Antitumor Activity against RET-Rearranged Non–Small Cell Lung Cancer

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• The Future of Cancer Genomics

  2014cited by this paper
• Activating HER2 mutations in HER2 gene amplification negative breast cancer.

  2013cited by this paper
• DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy

  2013cited by this paper
• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

  2013cited by this paper
• Flow Cytometry Bioinformatics

  2013cited by this paper
• EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

  2012cited by this paper
• ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

  2012cited by this paper
• KIF5B-RET fusions in lung adenocarcinoma

  2012cited by this paper
• Activating HER 2 Mutations in HER 2 Gene Amplifi cation Negative Breast Cancer

  2012cited by this paper
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• RET, ROS1 and ALK fusions in lung cancer

  2012cited by this paper
• Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

  2011cited by this paper
• EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

  2011cited by this paper
• CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.

  2011cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy

  2009cited by this paper
• Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

  2008cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation

  2003cited by this paper
• A new fluorometric assay for cytotoxicity measurements in-vitro.

  1993cited by this paper
• Mutation affecting the 12th amino acid of the c-Ha-ras oncogene product occurs infrequently in human cancer.

  1983cited by this paper

• Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients

  2025cites this paper
• Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

  2025cites this paper
• Integrative machine learning predicts activating kinase mutations for precision oncology

  2025cites this paper
• Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I

  2025cites this paper
• Advanced lung adenocarcinoma with rare EGFR exon 21 T854A mutation: a case report on increased dose osimertinib following resistance.

  2025cites this paper
• Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab

  2025influential citation
• Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR-TKI Administration Using Droplet Digital PCR in Non-small-cell Lung Cancer With EGFR Mutation

  2025cites this paper
• Functional Analysis of Rare RAS Variants of Unknown Significance

  2025cites this paper
• 伏美替尼敏感的EGFR 20号外显子H773_V774delinsLM突变肺腺癌1例

  2025cites this paper
• Case of a rare EGFR mutation L747P identified using the lung cancer compact Panel™ leading to successful Afatinib treatment

  2025cites this paper
• Two Cases of Epidermal Growth Factor Receptor L861R Mutation‐Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib

  2025cites this paper
• Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

  2025cites this paper
• Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasis

  2025cites this paper
• Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

  2025cites this paper
• A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N

  2025cites this paper
• Multiplexed assays of variant effect for clinical variant interpretation

  2025cites this paper
• Fungi and cancer: unveiling the complex role of fungal infections in tumor biology and therapeutic resistance

  2025cites this paper
• Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants

  2024cites this paper
• D3EGFR: a webserver for deep learning-guided drug sensitivity prediction and drug response information retrieval for EGFR mutation-driven lung cancer

  2024cites this paper
• Afatinib plus bevacizumab treatment for a patient with EGFR S645C-mutant NSCLC

  2024cites this paper
• A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges

  2024cites this paper
• EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer

  2024cites this paper
• GLI1 confers resistance to PARP inhibitors by activating the DNA damage repair pathway

  2024cites this paper
• The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

  2024influential citation
• Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C-Mutant Non-Small Cell Lung Cancer: A Case Report.

  2024cites this paper
• Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs

  2024cites this paper
• First-line Osimertinib for Lung Cancer With Uncommon EGFR Exon 19 Mutations and EGFR Compound Mutations

  2024cites this paper
• Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report

  2024cites this paper
• Saturation profiling of drug-resistant genetic variants using prime editing

  2024cites this paper
• EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report

  2024cites this paper
• Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

  2024cites this paper
• Efficacy and Safety of Chemotherapy or EGFR‐TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China

  2024cites this paper
• New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.

  2024cites this paper
• Treatment sequences in EGFR mutant advanced NSCLC.

  2024cites this paper
• Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report

  2024cites this paper
• Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

  2024cites this paper
• Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France

  2024cites this paper
• Multimodal scanning of genetic variants with base and prime editing

  2024cites this paper
• Clinical phase II trial shows that combining osimertinib and afatinib resistance EGFR recurrent mutation in EGFR-mutant lung cancer

  2024cites this paper
• Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors

  2024cites this paper
• RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

  2023cites this paper
• Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated non-small cell lung cancer

  2023cites this paper
• Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer

  2023influential citation
• Successful treatment of a patient with NSCLC carrying uncommon compound L861Q/G719X epidermal growth factor receptor mutations using Afatinib

  2023cites this paper
• Extensive analysis of 59 sarcoma‐related fusion genes identified pazopanib as a potential inhibitor to COL1A1‐PDGFB fusion gene

  2023cites this paper
• Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers

  2023cites this paper
• A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202

  2023cites this paper
• Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer

  2023cites this paper
• Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies

  2023cites this paper
• Cancer driver mutations: predictions and reality.

  2023cites this paper
• Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis

  2023cites this paper
• EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report

  2023cites this paper
• Multiple Mutations within Individual Oncogenes: Examples and Clinical Implications.

  2023cites this paper
• Actionability classification of variants of unknown significance correlates with functional effect

  2023cites this paper
• Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes

  2023cites this paper
• Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study

  2023cites this paper
• Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

  2023cites this paper
• Impact of RBM10 and PD-L1 expression on the prognosis of pathologic N1–N2 epidermal growth factor receptor mutant lung adenocarcinoma

  2023cites this paper
• Rare case of de novo EGFR L718V mutation-positive non-small cell lung cancer successfully treated with afatinib

  2023cites this paper
• The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

  2023cites this paper
• Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review

  2023cites this paper
• Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer

  2023cites this paper
• The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics.

  2023cites this paper
• Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.

  2023cites this paper
• A lung adenocarcinoma with rare epidermal growth factor receptor exon 20 V774M mutation was sensitive to osimertinib: A case report and molecular structural analysis.

  2023cites this paper
• Non-small-cell lung cancer: how to manage EGFR-mutated disease

  2022cites this paper
• Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine

  2022cites this paper
• Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC

  2022cites this paper
• Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

  2022cites this paper
• UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN).

  2022cites this paper
• Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis

  2022cites this paper
• A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

  2022cites this paper
• RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

  2022cites this paper
• Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)

  2022cites this paper
• Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)

  2022cites this paper
• Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model

  2022cites this paper
• EGFR signaling pathway as therapeutic target in human cancers.

  2022cites this paper
• Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

  2022influential citation
• Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.

  2022cites this paper
• An oncogenic splice variant of PDGFRα in adult glioblastoma as a therapeutic target for selective CDK4/6 inhibitors

  2022cites this paper
• Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib

  2022cites this paper
• Absence of copy number gain of EGFR: A possible predictive marker of long‐term response to afatinib

  2022cites this paper
• Nucleic acid analysis on electrowetting-based digital microfluidics

  2022cites this paper
• High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer

  2022cites this paper
• Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias

  2022cites this paper
• Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation

  2022cites this paper
• Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X

  2022cites this paper
• Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone

  2022cites this paper
• Journal Pre-proof UNcommon EGFR mutations: International Case series on efficacy of osimertinib in Real-life practice in first liNe setting (UNICORN) Real-life

  2022cites this paper
• An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations

  2022cites this paper
• Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis

  2022influential citation
• C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

  2022cites this paper
• Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

  2022cites this paper
• First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea

  2022cites this paper
• Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.

  2022cites this paper
• Efficacy and potential resistance mechanisms of afatinib in advanced non–small cell lung cancer patients with EGFR G719X/L861Q/S768I

  2022cites this paper
• Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

  2022cites this paper
• Defining the Sensitivity Landscape of EGFR Variants to Tyrosine Kinase Inhibitors.

  2022cites this paper
• Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea

  2021influential citation
• De ning the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase Inhibitors

  2021cites this paper